Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Department of Error] Department of Error

Powles T, Durán I, van der Heijden M, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748–57—In the Results section of this Article, in the sentence that reads “For patients receiving chemotherapy, vinflunine outperformed study expectations; unstratified HRs were 0·95 (95% CI 0·62–1·45) and 0·69 (0·44–1·10) in subgroups based on chemotherapy stratification with vinflunine (n=106) and taxanes (n=128), respectively”, the totals for vinflunine and taxanes are the wrong way around.